2023
Evolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma.
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Evolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2023, 41: 610-610. DOI: 10.1200/jco.2023.41.6_suppl.610.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsOral anti-cancer agentsNon-Hispanic white patientsSystemic therapyRenal cell carcinomaNHW patientsWhite patientsCell carcinomaMedicare beneficiariesService Medicare Parts ARetrospective cohort studyOverall treatment rateMedicare Part AIO therapyMRCC therapyAnti-cancer agentsCheckpoint inhibitorsCohort studyOlder patientsRandomized trialsSurvival improvementFirst therapyStudy criteriaTreatment receipt
2014
Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007. Journal Of Clinical Oncology 2014, 32: 309-309. DOI: 10.1200/jco.2014.32.30_suppl.309.Peer-Reviewed Original ResearchReceipt of chemotherapyChemotherapy utilizationOncotype DXRisk diseaseBreast cancerODX testingEarly-stage estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerER-positive breast cancerIntermediate-risk diseaseHigh-risk patientsHigh-risk diseasePositive breast cancerBreast cancer populationAdjuvant chemotherapyNCCN guidelinesRisk patientsPathologic featuresRandomized trialsStudy criteriaCancer populationObservational studyRetrospective analysis
2012
Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial
DeWitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, Reed SD. Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial. Value In Health 2012, 15: 277-283. PMID: 22433759, DOI: 10.1016/j.jval.2011.11.027.Peer-Reviewed Original ResearchConceptsLung functionMild impairmentCystic fibrosisClinical trialsAeruginosa colonizationHealth Utilities Index Mark 2/3Study case report formsPrimary end pointNationwide Inpatient SampleDirect medical costsMulticenter clinical trialP. aeruginosa colonizationPseudomonas aeruginosa colonizationMean annual costCase report formsLong-term useUtility estimatesEmergency visitsHospital admissionDornase alfaMedication costsRandomized trialsMean ageFemale sexInpatient Sample